Analysts Set DRI Healthcare Trust (TSE:DHT.UN) Target Price at C$17.94

DRI Healthcare Trust (TSE:DHT.UN) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is C$17.94.

A number of brokerages have commented on DHT.UN. CIBC reduced their price target on shares of DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a research report on Thursday, December 12th. National Bankshares reduced their price objective on DRI Healthcare Trust from C$19.50 to C$17.50 and set an “outperform” rating on the stock in a research note on Thursday, February 20th.

DRI Healthcare Trust Price Performance

DHT.UN stock opened at C$11.13 on Wednesday. The firm has a 50 day simple moving average of C$11.76 and a two-hundred day simple moving average of C$12.45. DRI Healthcare Trust has a one year low of C$10.39 and a one year high of C$17.43.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.